Search Results 61-70 of 16677 for Lou Gehrig's disease
... ALS/FTD to characterize pre-symptomatic ALS/FTD disease states. Participation eligibility. Participant eligibility includes age, gender, type and stage of ...
The purpose of this study is to identify patients with a diagnosis of Amyotrophic Lateral Disease (ALS) or ALS variants who have laboratory markers of ...
including muscular dystrophy and amyotrophic lateral sclerosis (Lou Gehrig's disease) ... are often debilitating and sometimes fatal. On this week's program, we ...
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 in Amyotrophic Lateral Sclerosis (ALS) Patients.
Over the course of two years, I had various diagnosis, anywhere from ALS to, I think it's Lou Gehrig's disease, Parkinson's. But they never could get to ...
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a rapidly progressive, uniformly fatal neurodegenerative disease. It is ...
There are no readily available sources of longitudinal CSF, plasma or serum samples from people with ALS, ALS-FTD or similar neurodegenerative disorders or ...
The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB067 in participants with amyotrophic lateral sclerosis (ALS) and ...
For each patient, the times from disease onset to abnormal overnight pulse oximetry, maximum inspiratory pressure and forced vital capacity testing results were ...
This debilitating early-onset neuro-degenerative disorder has ties to Alzheimer's and Lou Gehrig's disease, also known as amyotrophic lateral sclerosis, or ALS.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.